Amgen : Tezepelumab Is the First Biologic To Significantly Reduce Exacerbations in Broad Population of Patients with Severe, Uncontrolled Asthma

THOUSAND OAKS - Amgen (NASDAQ: AMGN) and AstraZeneca today announced positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential of tezepelumab to be a first-in-class medicine in severe asthma.

When added to standard of care (SoC), tezepelumab demonstrated a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER) in patients with severe, uncontrolled asthma, compared to placebo.1 The results were presented at the American Academy of Asthma Allergy & Immunology Annual Meeting. NAVIGATOR is a pivotal Phase 3 trial that will form the basis of regulatory filing.

Tezepelumab, a potential first-in-class medicine, when added to standard of care (SoC) achieved a 56% reduction (p

(C) 2021 Electronic News Publishing, source ENP Newswire